-
Innovation Ranking
NewInnovation Ranking – Vaxart Inc
Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VXAG-1.1NN in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VXAG-1.1NN in Norovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VXAG-1.1NN in Norovirus Infections Drug Details: VXAG-1.1NN is under development for the prevention...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AGEN-2373 in Vulvar Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AGEN-2373 in Vulvar Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AGEN-2373 in Vulvar Cancer Drug Details: AGEN-2373 is under development for the...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer - Drugs In Development, 2023’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H1N1 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Simplexvirus (HSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Simplexvirus (HSV) Infections - Drugs In Development, 2023’, provides an overview of the Simplexvirus (HSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Simplexvirus (HSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Seasonal Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Influenza - Drugs In Development, 2023’, provides an overview of the Seasonal Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chikungunya Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Chikungunya Fever - Drugs In Development, 2023’, provides an overview of the Chikungunya Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Avian Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Avian Influenza - Drugs In Development, 2023’, provides an overview of the Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...